Not losing weight on semaglutide: first verify the treatment being assessed
A slow or absent change needs a product-specific, time-specific response review. Early escalation, interrupted use, a later plateau and no response after an adequate clinician-documented trial are different questions.
If weight has not changed as expected on semaglutide, the first question is what product and treatment phase are actually being assessed. An early period while a clinician is still adjusting treatment, interruptions in access or use, a stable plateau after initial loss, and little response after a fully reviewed course are not one problem. Check the named product, indication, timeline, measures, tolerability and agreed goal with the prescriber before calling it “not working” or changing medicine yourself. Clinical-trial averages are not a personal deadline.1234
A shared ingredient is not a shared treatment record
Semaglutide appears in products with different labels and delivery forms. Wegovy has weight-management indications; Ozempic’s label is centered on type 2 diabetes and other specified diabetes-related outcomes, not a general obesity indication. As of the current labels, both injectable and oral product forms exist, so “I am on semaglutide” does not tell a reviewer the exact regimen. Record the brand, formulation, pharmacy source, indication and clinician’s plan rather than borrowing expectations from a study of another product.12
| Situation | What it means for the review | Question to ask |
|---|---|---|
| Treatment was started recently | The product may still be in a clinician-managed introduction phase | What phase are we evaluating, and when is a meaningful review planned? |
| Access or use was interrupted | The observed exposure may differ from the planned course | How should we document interruptions and revise follow-up? |
| Weight fell, then stabilized | A later plateau is not the same as never responding | What trend and other goals should we reassess now? |
| Little change after a reviewed course | The prescriber may reconsider benefit, tolerability and alternatives | What was the agreed outcome, and what evidence supports a change? |
This is not a dosing chart. Wegovy’s prescribing information describes product- and route-specific treatment phases and clinical-study populations. Those details belong to the prescribing clinician, especially if a person missed doses or changed formulations. An internet timetable that tells everyone to increase, restart or switch on the same week is not a safe substitute for the product’s instructions and an individual assessment.1
Measure the same question twice
A useful response review compares a documented baseline with the same kind of measure later. Weight recorded on different scales, at different times of day, or after a long gap may not tell the whole story. The clinician may also consider waist measures, metabolic indicators, symptoms, ability to sustain the plan, side effects and the person’s stated goal. ADA’s 2026 standards frame obesity care as ongoing and individualized rather than a single number detached from context.3
The original STEP 1 study followed a defined group for 68 weeks using a particular injectable semaglutide regimen and lifestyle intervention. Its group-average result cannot predict what will happen after a few weeks for a given patient, nor can it be pasted onto an Ozempic, oral semaglutide or compounded-product offer. If a clinic quotes a percentage, ask which original study and product it comes from, who was enrolled and when the outcome was measured.4
Distinguish a problem with the plan from a problem with the drug
Ask whether the care plan includes predictable follow-up, a way to report tolerability, help with product access and a clear response measure. These are delivery-of-care questions, not accusations that the patient did something wrong. A clinician can evaluate whether a limited observed response reflects duration, a different indication, an interruption, another health issue, an unrealistic benchmark or a treatment that should be reconsidered. An article cannot assign that cause.
If the offer came through telehealth or an online subscription, verify the exact dispensed product and pharmacy, not just the active ingredient in advertising. A compounded semaglutide product is not an FDA-approved Wegovy or Ozempic product. Likewise, a switch to tirzepatide is a separate clinical decision, not the automatic next step after one disappointing weigh-in. The switching guide covers that handoff after a response review has actually occurred.
Use Treomark’s medical weight-management provider page to compare consultations that include follow-up, not merely a prescription access point. A strong answer can tell you what is being measured, when it is fair to judge that particular regimen, and how the plan changes if benefit and burden do not line up.
Sources
- National Library of Medicine DailyMed. Wegovy prescribing information. Current product-specific weight-management indication, forms, study populations and clinician-managed treatment phases. Accessed .
- National Library of Medicine DailyMed. Ozempic injection prescribing information. Distinct diabetes-context semaglutide product and indications; not interchangeable with a Wegovy weight-management label. Accessed .
- American Diabetes Association. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2026. Guideline context for individualized goals, efficacy, tolerability and ongoing weight-management assessment. Accessed .
- New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Original 68-week Wegovy-dose injection trial; a group result, not a personal early-response target or an Ozempic/oral-product forecast. Accessed .